Ladarixin, an allosteric non-competitive CXCR1 and CXCR2 antagonist, delayed the onset of diabetes and improved glycemic control when administered following multiple low-dose STZ injections in C57BL/6 mice (45). This evidence concerns the gene CXCR2 and diabetes mellitus.